ArticleAJNR. American journal of neuroradiology2019
Outcome Study of the Pipeline Embolization Device with Shield Technology in Unruptured Aneurysms (PEDSU).
Article in AJNR. American journal of neuroradiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05626504 (Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Clinical outcomes of pipeline embolization devices with shield technology for treating intracranial aneurysms.Frontiers in neurology · 2022Pooled it
- Outcome of Flow Diverters with Surface Modifications in Treatment of Cerebral Aneurysms: Systematic Review and Meta-analysis.AJNR. American journal of neuroradiology · 2021Pooled it
- Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study.Neuroradiology · 2026Article
- Angiographic and clinical outcomes from 396 aneurysms treated with the pipeline flex embolization device with shield technology.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026Article
- First clinical experience with the surpass elite flow diverter in the treatment of intracranial aneurysms.Neuroradiology · 2026Article
- Efficacy and Safety in the Use of Pipeline Vantage Shield Stent versus Pipeline Flex Shield Stent in the Treatment of Patients with Unruptured Intracranial Aneurysms: A Multicenter Study.AJNR. American journal of neuroradiology · 2025Article
- Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.Clinical neuroradiology · 2025Article
- Outcome study of the Pipeline Vantage Embolization Device (second version) in unruptured (and ruptured) aneurysms (PEDVU(R) study).Journal of neurointerventional surgery · 2024Article
- Multicenter Experience with the Pipeline Flex and Vantage with Shield Technology for Intracranial Aneurysm Treatment.AJNR. American journal of neuroradiology · 2024Observational
- Treatment Outcomes of PED for Unruptured Aneurysms of Internal Carotid Artery: Comparison of PED-Flex and PED-Shield.Neurologia medico-chirurgica · 2024Article
- Endovascular treatment for anterior inferior cerebellar artery-posterior inferior cerebellar artery (AICA-PICA) common trunk variant aneurysms: Technical note and literature review.Journal of cerebrovascular and endovascular neurosurgery · 2023Article
- Early Outcomes of the Pipeline Vantage Flow Diverter : A Multicentre Study.Clinical neuroradiology · 2023Review
- Safety and Clinical Effectiveness of Pipeline Shield Device for Intracranial Aneurysms in an Australian Cohort (SCOPE-AUS).Stroke (Hoboken, N.J.) · 2022Article
- Postprocedural Thrombosis following Endovascular Treatment of Intracranial Aneurysm with Flow Diverters or Coiling: A Histologic Study.AJNR. American journal of neuroradiology · 2022Article
- Endovascular Treatment of Intracranial Aneurysms.Life (Basel, Switzerland) · 2021Review
- The Aneurysm Occlusion Assistant, an AI platform for real time surgical guidance of intracranial aneurysms.Proceedings of SPIE--the International Society for Optical Engineering · 2021Article
- Periprocedural to 1-year safety and efficacy outcomes with the Pipeline Embolization Device with Shield technology for intracranial aneurysms: a prospective, post-market, multi-center study.Journal of neurointerventional surgery · 2020Observational
- Hydrophilic Surface Coating of Flow Diverters: A Possible Way to Omit Dual Platelet Aggregation Inhibition.Cardiovascular and interventional radiology · 2020Article
- Advances in endovascular aneurysm management: flow modulation techniques with braided mesh devices.Stroke and vascular neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 5 countries.
Funding
Abstract
background and purposeThe recently introduced Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield) is the third generation of Pipeline flow-diverter devices. It has a new stent-surface modification, which reduces thrombogenicity. We aimed to evaluate clinical and radiographic (safety and efficacy) outcomes of the Pipeline Shield. MATERIALS AND
methodsThe 30-day and 1-year mortality and morbidity rates and the 6- and 18-month radiographic aneurysm occlusion outcomes for procedures performed between March 2016 and January 2018 were analyzed. 3D-TOF-MRA was used for follow-up.
resultsForty-four attempted Pipeline Shield procedures were performed for 41 patients with 44 target aneurysms (total of 52 aneurysms treated). A total of 88.5% of devices were inserted in the anterior circulation, and 11.5%, in the posterior circulation; 49/52 (94.2%) aneurysms were saccular; and 1/52 (1.9%) was fusiform. One (1.9%) aneurysm was an iatrogenic pseudoaneurysm, and 1 (1.9%) was a dissecting aneurysm. Seventy-one percent (35/49) of the saccular aneurysms were wide-neck (neck, >4 mm), 34.6% (18/52) were large (≥10 mm), and 3.8% (2/52) were giant (≥25 mm). The mean aneurysm sac maximal diameter was 9.0 mm, and the mean neck width was 5.0 mm. The cumulative mortality and morbidity rates were 2.3% and 6.8% at 1 year, respectively. The adequate occlusion rate was 78.8% at 6 months and 90.3% at 18 months.
conclusionsIn this pragmatic and non-industry-sponsored study, the occlusion rates and safety outcomes were similar to those seen in previously published studies with flow-diverter devices and earlier generation Pipeline Embolization Devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.